carbenoxolone sodium has been researched along with triletide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbarino, C; Bivona, A; Campisi, D; Cataldo, MG; Paterna, S | 1 |
| Bergamaschi, M; Caliari, S; Fossati, A; Gervasi, GB; Rapalli, L | 1 |
1 trial(s) available for carbenoxolone sodium and triletide
| Article | Year |
|---|---|
Cytoprotective therapy of gastric ulcers: a controlled clinical evaluation of triletide versus carbenoxolone.
Topics: Adult; Antacids; Anti-Ulcer Agents; Carbenoxolone; Clinical Trials as Topic; Female; Glycyrrhetinic Acid; Humans; Male; Middle Aged; Oligopeptides; Random Allocation; Stomach Ulcer; Time Factors | 1985 |
1 other study(ies) available for carbenoxolone sodium and triletide
| Article | Year |
|---|---|
Prevention of experimentally induced gastric damage with the tripeptide ZAMI-420, a new thromboxane synthesis inhibitor.
Topics: Animals; Arachidonic Acids; Biological Assay; Carbenoxolone; Chromatography, Thin Layer; Cimetidine; Ethanol; Female; Guinea Pigs; Imidazoles; Oligopeptides; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Rabbits; Radioimmunoassay; Rats; Rats, Inbred Strains; Serotonin; Stomach; Stomach Ulcer; Thromboxane A2; Thromboxanes; Vasoconstriction | 1983 |